Project Grant R43AI192105
Award Date 8/12/25
Completion Date 7/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $242,250.00 to researchers at the University of Virginia to develop a vaccine against cryptosporidiosis, a common cause of diarrheal disease in sub-Saharan Africa and Asia. The goal is to create a liposomal vaccine formulation that stimulates both cellular and humoral immunity targeting the extracellular and intracellular life stages of the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $223,176 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the University of Pennsylvania to support research on the molecular architecture of the Cryptosporidium host-parasite interface. This research aims to better understand the intricate ultrastructural features and function of the interface between the Cryptosporidium parasite and its host cells, as...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This $715,894 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research to elucidate the role of microbial metabolites in influencing mitosome function in the enteric pathogen Cryptosporidium. The primary objectives are to characterize the function of an ADP/ATP carrier in generating the mitosome's membrane potential, determine the role of a putative pyridoxal...
- This Project Grant award of $458,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a VP4-based pseudovirus nanoparticle rotavirus vaccine for oral immunization. The award will fund research to create a non-replicating rotavirus vaccine candidate called S-VP4E, which consists of a calicivirus inner shell and multiple rotavirus spikes (VP4E) on the surface. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The grant aims to develop two innovative vaccine candidates to prevent pulmonary nontuberculous mycobacterial (NTM) infections, which have surpassed tuberculosis as a global health concern. The research involves screening 13 vaccine...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
- This $300,000 Project Grant was awarded on August 25, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855). The purpose is to develop a sensitive and specific serological test for evaluating the potency of whole cell pertussis (whooping cough) vaccines. The awardee, Immport Therapeutics Inc. (doing business as Antigen Discovery Inc.), will use a Bordetella pertussis proteome microarray to identify...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,193,457 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMASS Medical) to produce, validate, and provide relevant fungal antigens to the scientific community. The funding will support the manufacturing of crude antigenic preparations from various fungal pathogens, as well as the recombinant production and testing of 36...